StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Cubicin (daptomycin, legacy) — U.S. sales by Quarter

Cubicin (daptomycin, legacy) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Cubicin (daptomycin, legacy) — U.S. sales: $10M in Q4 2020, down 23.1% from a year earlier. That is the lowest of the 17 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2020
10
Period ended Dec 31, 2020
Change on a year earlier
-23.1%
13 in Q4 2019
History
17 quarters
Since Q4 2016
Sources
13
Documents cited below

Where the Q4 2020 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2021-02-25) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCubicin (daptomycin, legacy) — U.S. sales ($M) ($M)Year on yearSource
Q4 2020Dec 31, 202010-23.1%Form 10-K (filed 2021-02-25) ↗
Q3 2020Sep 30, 202011-21.4%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2020Jun 30, 202010-54.5%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 202015-64.3%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2019Dec 31, 201913-68.3%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2019Sep 30, 201914-74.5%Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗
Q2 2019Jun 30, 201922-54.2%Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗
Q1 2019Mar 31, 201942-10.6%Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗
Q4 2018Dec 31, 201841+2.5%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
Q3 2018Sep 30, 201855+34.1%Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗
Q2 2018Jun 30, 201848-9.4%Form 8-K (a19-15283_1ex99d1.htm, filed 2019-07-30) ↗
Q1 2018Mar 31, 201847-13.0%Form 8-K (a19-8996_1ex99d1.htm, filed 2019-04-30) ↗
Q4 2017Dec 31, 201740-51.2%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
Q3 2017Sep 30, 201741–Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗
Q2 2017Jun 30, 201753–Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗
Q1 2017Mar 31, 201754–Form 8-K (a18-12417_1ex99d1.htm, filed 2018-05-01) ↗

Breakdown

What makes up cubicin (daptomycin, legacy) — U.S. sales

Cite this data

StockData. (2026). Merck Cubicin (daptomycin, legacy) — U.S. sales ($M), quarterly Q4 2016–Q4 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-cubicin-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.